21st International Congress » Huntington's Disease

1:45pm-3:15pm

Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation

C. Fitzer-Attas, D. Stephenson, K. Romero, J. Neville, C. Sampaio (Critical Path Institute, Tucson, AZ; CHDI Foundation, Princeton, NJ)

1:45pm-3:15pm

A Descriptive Analysis of a Real-World Population With Huntington Disease-Associated Chorea (HDAC) Treated With Tetrabenazine: Findings From an Electronic Medical Records (EMR) Database

R. Iver, D. Alevras, S. Gandhi, T. Schilling, V. Abler, F. Cao, K. Johnson, K. Anderson (Frazer, PA, USA)

1:45pm-3:15pm

A modified model for prediction of Huntington disease age of onset based on length of CAG repeat expansion

Y. Seliverstov, E. Shulgina, S. Illarioshkin, M. Belyaev (Moscow, Russian Federation)

1:45pm-3:15pm

A retrospective analysis of clinical forms and age of onset of biallelic Huntington disease patients from an Argentinean Center

M. Cesarini, V. Parisi, G. Persi, J. Etcheverry, A. Sanguinetti, F. Squitieri, E. Gatto (Buenos Aires, Argentina)

1:45pm-3:15pm

Admission Diagnoses and Eventual Discharge Dispositions for Hospitalized Huntington’s Disease Patients: Results of a Nationwide Survey

S. Gupta, F. Benesh, V. Sung (Birmingham, AL, USA)

1:45pm-3:15pm

Baseline multimodal information predicts future motor impairment in premanifest Huntington’s disease

E. Castro, P. Polosecki, I. Rish, G. Cecchi (Yorktown Heights, NY, USA)

1:45pm-3:15pm

Behavioral Changes on the UCSD Huntington’s Disease Behavioral Questionnaire (HD-BQ) Distinguish Patients Transitioning to Manifest Huntington’s disease (HD)

S. Park, S. Nam, A. Nathan, A. Haque, A. Haque, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

1:45pm-3:15pm

Cerebrospinal fluid biomarkers in Huntington’s disease – a longitudinal study

V. Niemelä, J. Sundblom, A.-M. Landtblom, S. Herman, K. Kultema, D. Nyholm, K. Blennow (Uppsala, Sweden)

1:45pm-3:15pm

Clinical and genetic characterization of Huntington’s disease in relation to the age and type of onset.

L. Mendoza Vega, M. Rodríguez-Violante, A. Cervantes-Arriaga, A. De-la-Cruz-Landero, N. Davila-Avila, K. Salinas-Barboza, S. Isais-Millan (Mexico City, Mexico)

1:45pm-3:15pm

Demographic and Clinical Characteristics and Tetrabenazine (TBZ) Persistence in Patients With Huntington Disease (HD)-Associated Chorea

V. Sung, R. Iyer, S. Gandhi, V. Abler, B. Davis, D. Irwin, K. Anderson (Birmingham, AL, USA)

1:45pm-3:15pm

Depression among Inpatients with Huntington’s Disease: Patient Characteristics and Outcomes

F.S. Benesh, S. Gupta, V. Sung (Birmingham, AL, USA)

1:45pm-3:15pm

Dopamine transporter scan finding in patients with chorea.

K. Kawabe, K. Miura, K. Ikeda, Y. Iwasaki (Tokyo, Japan)

1:45pm-3:15pm

Down-regulation of miR-9* in the peripheral leukocytes of Huntington’s Disease patients

K.-H. Chang, Y.-R. Wu, C.-M. Chen (Taoyuan County, Taiwan)

1:45pm-3:15pm

Dynamic prediction of motor diagnosis in Huntington’s disease using a joint modeling approach

K. Li, E. Furr Stimming, S. Luo, K. Li (Houston, TX, USA)

1:45pm-3:15pm

Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): Results of a Cohort Comparison of Open-HART and Historical Placebo Subjects

A. McGarry, V. Abler, P. Auinger, I. Grachev, S. Gandhi, S. Papapetropoulos (Camden, NJ, USA)

1:45pm-3:15pm

Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD

R. Reilmann, A. McGarry, G. Landwehrmeyer, K. Kieburtz, I. Grachev, E. Eyal, J. Savola, B. Borowsky, S. Papapetropoulos, M. Hayden (Münster, Germany)

1:45pm-3:15pm

Evidence-based Brazilian Physicaltherapy Guideline for Huntington´s Disease

T. Capato, M. Haddad, E. Barbosa, M.E. Piemonte (Sao Paulo, Brazil)

1:45pm-3:15pm

Examining central cognitive processing speed as an early marker of Huntington’s disease (HD) onset

A. Nathan, S. Park, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

1:45pm-3:15pm

Factors Influencing Completion of Predictive Testing for Huntington’s Disease (HD)

M. Patel, V. Sung (Birmingham, AL, USA)

1:45pm-3:15pm

Gait Analysis in Patients with Huntington’s Disease

Y.-M. Park, S. Pyo, H.-M. Lee, M.-J. Kim, S.-B. Koh (Seoul, Republic of Korea)

1:45pm-3:15pm

Hung up knee jerk reflex in Huntington’s disease: A clinical and neurophysiological study

J. Perez-Perez, J. Diaz-Manera, J. Pagonabarraga, S. Martinez-Horta, M. Carceller, A. Horta, J. Marin, H. Bejr-Kasen, A. Guerrero, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm

Huntington’s disease in the Republic of Tatarstan, epidemiological features

S. Munasipova, Z. Zalyalova (Kazan, Russian Federation)

1:45pm-3:15pm

Huntington’s Disease: Determinants for Cognitive Disease Progression – A Proposed Model

N. Gonçalves, J. Mendes, J. Ferreira, C. Sampaio (Lisbon, Portugal)

1:45pm-3:15pm

Imaging of phosphodiesterase 10 A (PDE10A) enzyme levels in the living human brain of Huntington’s disease gene expansion carriers and healthy controls with positron emission tomography.

P. Fazio, C. Fittzer-Attas, J. Bronzova, S. Nag, J. Warner, B. Landwehrmeyer, N. Al-Tawil, C. Halldin, L. Mrzljak, C. Sampaio, A. Varrone (Stockholm, Sweden)

1:45pm-3:15pm

Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington Disease in a Phase II Clinical Trial

S. Papapetropoulos, S. Fine, E. Cohen, C. Admati, Y. Dolan, I. Grachev, I. Grossman, M. Hayden (Petach Tikva, Israel)

1:45pm-3:15pm

Inhibiting sphingosine-1-phosphate lyase as a possible therapy in Huntington’s disease

E. Furr Stimming, J.F. Manchon, A. Tsvetkov (Houston, TX, USA)

1:45pm-3:15pm

Juvenile Huntington Disease (JHD) subjects’ stratification according to the mutation-length

M. Marano, M. Marano, S. Migliore, S. Maffi, F. Consoli, A. Ciammola, E. Gatto, F. Squitieri (Rome, Italy)

1:45pm-3:15pm

Large CAG expansions in Huntington disease children: the RAREST-JHD initiative

F. Squitieri, M. Marano, S. Migliore, S. Maffi, F. consoli, E. Bidollari, J. Rosati, A. Ciammola, E. Gatto, E. Cortes, A. Ilari, J. Vonsattel, U. Sabatini (Rome, Italy)

1:45pm-3:15pm

Longitudinal Study of Cortico-Striatal Functional Connectivity in Huntington’s Disease Measured with High-Field Functional MRI.

M. Kronenbuerger, M. Kronenbuerger, J. Hua, X. Mia, P. Unschuld, P. van Zijl, C. Ross (Baltimore, MD, USA)

1:45pm-3:15pm

Myoclonus in adult onset Huntington’s disease

S. McAllister, S. Shipley, J. Shah, R. Fekete (New York, NY, USA)

1:45pm-3:15pm

Myths and Misconceptions Regarding Huntington’s Disease in Peru

A. Vishnevetsky, M. Illanes-Manrique, M. Inca-Martinez, M. Cornejo-Olivas (Philadelphia, PA, USA)

1:45pm-3:15pm

Predictors for psychosis in Huntington’s disease: preliminary analysis of the Enroll-HD database.

N. Rocha, E. Furr-Stimming, A. Teixeira (Houston, TX, USA)

1:45pm-3:15pm

Prescription pattern of treatment in Mexican patients with Huntington’s Disease.

A. De-la-Cruz, L. Mendoza Vega, N. Davila Avila, K. Salinas Barboza, S. Isais Millan, A. Cervantes Arriaga, M. Rodriguez Violante (Ciudad de Mexico, Mexico)

1:45pm-3:15pm

Prevalence of substance abuse in Huntington´s disease patients and its relationship with neuropsychiatric symptoms

K. SALINAS BARBOZA, L. MENDOZA VEGA, A. CRUZ LANDERO, S. ISAIS MILLAN, M. RODRIGUEZ VIOLANTE, A. CERVANTES ARRIAGA, N. DAVILA AVILA (MEXICO, Mexico)

1:45pm-3:15pm

Progressive microstructural abnormalities of the occipital cortex in Huntington’s disease

O. Odish, R. Reijntjes, S. van_den Bogaard, R. Roos, A. Leemans (Leiden, Netherlands)

1:45pm-3:15pm

Rice bran extract against animal model of Huntington’s disease: Possible role of neurotransmitters

P. Kumar, N. Kaur (Bathinda, Punjab, India)

1:45pm-3:15pm

Salivary biomarkers for Huntington’s disease (HD)

J. Corey-Bloom, A. Aikin, S. Park, A. Haque, A. Nathan, D. Granger, S. Granger, E. Thomas (La Jolla, CA, USA)

1:45pm-3:15pm

Screening of cognitive impairment in Huntington’s disease with the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS)

S. Martinez-Horta, A. Horta-Barba, J. Perez-Perez, J. Pagonabarraga, J. Marin-Lahoz, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm

Sensory modulation of postural control in Huntington’s disease

F. Porciuncula, K. Marder, P. Wasserman, A. Rao (New York, NY, USA)

1:45pm-3:15pm

Social hindrances for diagnosing Huntington’s disease

A. Alboudi, P. Sarathchandran, A.B. Almadani (Dubai, United Arab Emirates)

1:45pm-3:15pm

The Huntington’s Disease Health Index Study (HD-HI)

A. Glidden, E. Luebbe, M. Elson, S. Goldenthal, R. Dorsey, C. Heatwole (Rochester, NY, USA)

1:45pm-3:15pm

The Long-Term Safety of Deutetrabenazine for Chorea in Huntington Disease

S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)

1:45pm-3:15pm

The neural correlates of apathy in premanifest and manifest Huntington’s disease: A cross-sectional multimodal imaging study

S. Martinez-Horta, J. Perez-Perez, F. Sampedro, M. Carceller, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm

Update on the MDS-Sponsored Systematic Review On Clinical Rating Scales for Huntington’s Disease: motor, cognitive, functional ability and quality of life domains

T. Mestre, C. Sampaio, C. Goetz, P. Martinez-Martin, G. Stebbins (Ottawa, ON, Canada)